← Back to Search

MDM2 Inhibitor

KRT-232 for Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by Kartos Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will assess the safety and efficacy of KRT-232 in treating patients with small cell lung cancer that has progressed after prior treatment.

Eligible Conditions
  • Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Upper arm
Secondary outcome measures
Upper arm
Duration of response (DOR) of each arm
Overall survival (OS) of each arm
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2Experimental Treatment1 Intervention
KRT-232 180 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
Group II: Arm 1Experimental Treatment1 Intervention
KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)

Find a Location

Who is running the clinical trial?

Kartos Therapeutics, Inc.Lead Sponsor
15 Previous Clinical Trials
1,447 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still looking for test subjects for this experiment?

"This trial is actively recruiting patients, based on the information available on clinicaltrials.gov. The trial was first posted on December 6th, 2021, and was most recently updated on June 15th, 2022."

Answered by AI

Does KRT-232 have a history of being studied?

"The development of KRT-232 began in 2017 at Huntsman Cancer Institute/University of Utah. Since then, 3 studies have completed and 13 more are underway; several of these latter trials taking place in Fort Myers, Ohio."

Answered by AI

How many people are included in this clinical trial?

"In order to carry out the study, 38 patients that meet the eligibility requirements must be recruited. Kartos Therapeutics, Inc. will oversee the trial from various locations, such as Florida Cancer Specialists - 3840 Broadway in Fort Myers and University Hospitals Cleveland Medical Center situated in Cleveland, Tennessee."

Answered by AI

Is this clinical trial taking place in multiple hospitals across the state?

"Currently, 9 different facilities are running this clinical trial. Some notable locations include Florida Cancer Specialists - 3840 Broadway in Fort Myers, University Hospitals Cleveland Medical Center in Cleveland, and Florida Cancer Specialists in West Palm Beach."

Answered by AI

What sorts of side effects does KRT-232 have on patients?

"Given that this is a Phase 2 trial and there is only data supporting safety but no efficacy, our team has given KRT-232 a score of 2."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
2021. "KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05027867.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top